Literature DB >> 20585134

In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.

Yun Cai1, Ran Li, Beibei Liang, Nan Bai, Youning Liu, Rui Wang.   

Abstract

The antimicrobial activities of colistin and other antibiotics against clinical Acinetobacter baumannii and the mutant prevention concentration (MPC) of colistin against multidrug-resistant A. baumannii were studied. All 70 stains tested were sensitive to colistin. The MPC range of colistin against 30 multidrug-resistant A. baumannii stains was approximately 32 to >128 microg/ml, and the MPC at which 90% of the isolates tested were prevented (MPC(90)) exceeded 128 microg/ml, which was much higher than the plasma concentration of colistin at the current recommended dosage. So, combination therapy for colistin treatment of A. baumannii would be prudent to slow the emergence of resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585134      PMCID: PMC2934956          DOI: 10.1128/AAC.00264-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Mutant selection window hypothesis updated.

Authors:  Karl Drlica; Xilin Zhao
Journal:  Clin Infect Dis       Date:  2007-01-24       Impact factor: 9.079

Review 2.  Polymyxin B: similarities to and differences from colistin (polymyxin E).

Authors:  Andrea Kwa; Sofia K Kasiakou; Vincent H Tam; Matthew E Falagas
Journal:  Expert Rev Anti Infect Ther       Date:  2007-10       Impact factor: 5.091

3.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

4.  Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.

Authors:  Nikolaos Markou; Sophia L Markantonis; Efthimios Dimitrakis; Dimitris Panidis; Eleni Boutzouka; Stylianos Karatzas; Petros Rafailidis; Haralampos Apostolakos; George Baltopoulos
Journal:  Clin Ther       Date:  2008-01       Impact factor: 3.393

Review 5.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

6.  Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea.

Authors:  Young Kyoung Park; Sook-In Jung; Kyong-Hwa Park; Hae Suk Cheong; Kyong Ran Peck; Jae-Hoon Song; Kwan Soo Ko
Journal:  Diagn Microbiol Infect Dis       Date:  2009-05       Impact factor: 2.803

Review 7.  Colistin in the 21st century.

Authors:  Roger L Nation; Jian Li
Journal:  Curr Opin Infect Dis       Date:  2009-12       Impact factor: 4.915

  7 in total
  8 in total

1.  Colistin Heteroresistance and Involvement of the PmrAB Regulatory System in Acinetobacter baumannii.

Authors:  Yannick Charretier; Seydina M Diene; Damien Baud; Sonia Chatellier; Emmanuelle Santiago-Allexant; Alex van Belkum; Ghislaine Guigon; Jacques Schrenzel
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

2.  Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.

Authors:  Q Mei; Y Ye; Y-L Zhu; J Cheng; X Chang; Y-Y Liu; H-R Li; J-B Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-26       Impact factor: 3.267

3.  Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes.

Authors:  Chengchun Sun; Junwen Hao; Meiqin Dou; Yanwen Gong
Journal:  J Antibiot (Tokyo)       Date:  2014-11-05       Impact factor: 2.649

4.  Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii.

Authors:  Alejandro Beceiro; Antonio Moreno; Nathalie Fernández; Juán A Vallejo; Jesús Aranda; Ben Adler; Marina Harper; John D Boyce; Germán Bou
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

5.  Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy.

Authors:  Nayara Helisandra Fedrigo; Danielle Rosani Shinohara; Josmar Mazucheli; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Frederico Severino Martins; Peijuan Zhu; Mingming Yu; Sherwin Kenneth B Sy; Maria Cristina Bronharo Tognim
Journal:  Sci Rep       Date:  2021-05-31       Impact factor: 4.379

6.  The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit.

Authors:  Giancarlo Ceccarelli; Alessandra Oliva; Gabriella d'Ettorre; Alessandra D'Abramo; Elena Caresta; Caterina Silvia Barbara; Maria Teresa Mascellino; Paola Papoff; Corrado Moretti; Vincenzo Vullo; Paolo Visca; Mario Venditti
Journal:  BMC Infect Dis       Date:  2015-09-30       Impact factor: 3.090

7.  In vivo bactericidal effect of colistin-linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii pneumonia.

Authors:  Xiao-Lin Ma; Yong-Zhong Guo; Yan-Min Wu; Wei-Tao Gong; Jie Sun; Zhen Huang
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

8.  Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii.

Authors:  H Nordqvist; L E Nilsson; C Claesson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-10       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.